MXPA02009904A - Derivados de apomorfina y metodos para su uso. - Google Patents

Derivados de apomorfina y metodos para su uso.

Info

Publication number
MXPA02009904A
MXPA02009904A MXPA02009904A MXPA02009904A MXPA02009904A MX PA02009904 A MXPA02009904 A MX PA02009904A MX PA02009904 A MXPA02009904 A MX PA02009904A MX PA02009904 A MXPA02009904 A MX PA02009904A MX PA02009904 A MXPA02009904 A MX PA02009904A
Authority
MX
Mexico
Prior art keywords
apomorphine
methods
derivative compounds
derivatives
apomorphine derivatives
Prior art date
Application number
MXPA02009904A
Other languages
English (en)
Spanish (es)
Inventor
Deborah Milkowski
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of MXPA02009904A publication Critical patent/MXPA02009904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
MXPA02009904A 2000-04-07 2001-03-29 Derivados de apomorfina y metodos para su uso. MXPA02009904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07
PCT/US2001/040393 WO2001076602A1 (en) 2000-04-07 2001-03-29 Apomorphine derivatives and methods for their use

Publications (1)

Publication Number Publication Date
MXPA02009904A true MXPA02009904A (es) 2004-09-06

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009904A MXPA02009904A (es) 2000-04-07 2001-03-29 Derivados de apomorfina y metodos para su uso.

Country Status (18)

Country Link
US (1) US6506765B2 (OSRAM)
EP (1) EP1284735A4 (OSRAM)
JP (1) JP2003532640A (OSRAM)
KR (1) KR20030036157A (OSRAM)
CN (1) CN1471395A (OSRAM)
AU (1) AU2001255818A1 (OSRAM)
BG (1) BG107217A (OSRAM)
BR (1) BR0109515A (OSRAM)
CA (1) CA2405419A1 (OSRAM)
CZ (1) CZ20023637A3 (OSRAM)
HU (1) HUP0301773A3 (OSRAM)
IL (1) IL151614A0 (OSRAM)
MX (1) MXPA02009904A (OSRAM)
NO (1) NO20024806D0 (OSRAM)
PL (1) PL361672A1 (OSRAM)
SK (1) SK15772002A3 (OSRAM)
WO (1) WO2001076602A1 (OSRAM)
ZA (1) ZA200207489B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6737042B2 (en) * 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2003080074A1 (en) * 2002-03-19 2003-10-02 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
JP5584415B2 (ja) 2005-10-12 2014-09-03 ユニメッド・ファーマシューティカルズ・エルエルシー 改良したテストステロンゲル製剤及び使用の方法
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
KR102712887B1 (ko) 2017-11-24 2024-10-02 하. 룬드벡 아크티에셀스카브 파킨슨병의 치료에 사용하기 위한 새로운 카테콜아민 전구약물
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US12398106B2 (en) 2019-05-21 2025-08-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113677675B (zh) 2019-05-21 2024-07-26 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US20240335379A1 (en) * 2021-08-05 2024-10-10 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
PT689438E (pt) 1993-03-26 2003-10-31 Franciscus Wilhelmus He Merkus Composicoes farmaceuticas para administracao intranasal de apomorfina
ATE189121T1 (de) 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
DK1035833T3 (da) 1997-12-02 2006-01-09 Archimedes Dev Ltd Sammensætning til nasal indgivelse
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
EP1175206A1 (en) * 1999-05-13 2002-01-30 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives

Also Published As

Publication number Publication date
AU2001255818A1 (en) 2001-10-23
KR20030036157A (ko) 2003-05-09
EP1284735A1 (en) 2003-02-26
CN1471395A (zh) 2004-01-28
HUP0301773A2 (hu) 2003-09-29
IL151614A0 (en) 2003-04-10
WO2001076602A1 (en) 2001-10-18
BG107217A (bg) 2003-05-30
CZ20023637A3 (cs) 2003-02-12
PL361672A1 (en) 2004-10-04
SK15772002A3 (sk) 2003-09-11
JP2003532640A (ja) 2003-11-05
EP1284735A4 (en) 2006-01-11
US6506765B2 (en) 2003-01-14
BR0109515A (pt) 2004-08-10
NO20024806D0 (no) 2002-10-04
CA2405419A1 (en) 2001-10-18
US20020002176A1 (en) 2002-01-03
ZA200207489B (en) 2003-12-18
HUP0301773A3 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
GB0005251D0 (en) Therapeutic compounds
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
AU3304400A (en) Tetrahydropyran derivatives and their use as therapeutic agents
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
MXPA02001667A (es) Composicion y metodo neuroterapeutico.
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
MY138883A (en) Use of asiatic acid for treatment of cencer
MY164077A (en) Compositions and uses of et743 for treating cancer
AU1122202A (en) Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
BG106461A (en) Methods and use of rapid onset of reactive serotonin inhibitors for treating sexual dysfunction
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
IL150125A0 (en) Novel compounds
GB0020504D0 (en) Therapeutic method
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.